CDNA as reported
CareDx, Inc. reported $413M of revenue over the trailing twelve months, +19% on the year before. 11 reported series are charted on this page, each one as filed.
$413M
Revenue, trailing twelve months · to Q1 2026 · +19% against the twelve months before
- Net Income
- −$8.2M
Net Income · −113% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$1.5M
Free Cash Flow · −49% year on year · trailing twelve months to Q1 2026
- Op Margin
- −4.4%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $413M | +19% | Q1 2026 |
| Net Income | −$8.2M | −113% | Q1 2026 |
| EPS | −$0.16 | −114% | Q1 2026 |
| Gross Margin | 66% | n/a | Q2 2020 · 23 quarters behind |
| Op Margin | −4.4% | n/a | Q1 2026 |
| Net Margin | −2.4% | n/a | Q1 2026 |
| ROE | 7.7% | n/a | Q1 2026 |
| ROA | 5.6% | n/a | Q1 2026 |
| ROIC | −30% | n/a | Q4 2019 · 25 quarters behind |
| Free Cash Flow | −$1.5M | −49% | Q1 2026 |
| P/E | 17.2 | n/a | Q3 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
CareDx, Inc. (CDNA) - Revenue & ProfitRevenue & ProfitCareDx, Inc. (CDNA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #8 of 29 by Smart Score